Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for...

Related Keywords

Sweden ,United States ,Canada ,Stockholm ,Sandesh Seth ,Hans Vitzthum ,Anders Edvell ,Lifesci Advisors ,Shadow Lake Group ,Exchange Commission ,Astellas Pharma Inc ,Actinium Pharmaceuticals Inc ,European Medicines Agency ,Committee For Medicinal Products Human Use ,Epicentrx Inc ,Memorial Sloan Kettering Cancer Center ,Fred Hutchinson Cancer Research Center ,Middle East ,Actinium Pharmaceuticals ,Immedica Pharma ,Antibody Radiation Conjugate ,Conventional Care ,Refractory Acute Myeloid Leukemia ,North Africa ,Lake Group ,Acute Myeloid Leukemia ,Orphan Drug Designation ,Scientific Advice ,Medicinal Products ,Human Use ,Marketing Authorization ,Antibody Radiation Conjugates ,Bone Marrow Transplant ,Gene Therapy ,Adoptive Cell Therapy ,Elderly Relapsed ,Memorial Sloan Kettering Cancer ,Antibody Warhead Enabling ,Astellas Pharma ,Looking Statements ,Sci Advisors ,Nc ,